Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

2017593 citationsJournal Articlebronze Open Access

Authors

Vicente E. Torres · Mayo Clinic

Arlene B. Chapman · University of Chicago

Olivier Devuyst · UCLouvain

Ron T. Gansevoort · University Medical Center Groningen

Ronald D. Perrone · Tufts Medical Center

Gary G. Koch · University of North Carolina at Chapel Hill

John Ouyang ·

Abstract

Tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1-year period in patients with later-stage ADPKD. (Funded by Otsuka Pharmaceuticals and Otsuka Pharmaceutical Development and Commercialization; REPRISE ClinicalTrials.gov number, NCT02160145 .).

Topics & Keywords

Genetic and Kidney Cyst Diseases Biomedical Research and Pathophysiology Dialysis and Renal Disease Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 20, pp. 1930-1942

DOI: 10.1056/nejmoa1710030

Field-Weighted Citation Impact: 45.67